730
S. Jaju et al.
Arch. Pharm. Chem. Life Sci. 2009, 342, 723–731
Table 5. The in-vitro antimycobacterial activity of compounds
2a–g and 3a–g against M. tuberculosis H37Rv strain.
the lowest drug concentration, which prevented a color change
from blue to pink.
Compound
MICa)
2a
2b
2c
2d
2e
2f
2g
3a
3b
3c
3d
3e
3f
3g
resistant
0.62
1.25
3.12
5.0
1.25
0.31
resistant
0.62
1.25
5.0
References
[1] A. K. Dutt, W. W. Stead in Tuberculosis and Nontuberculosis
Mycobacterial Infections, 4th Ed, (Ed.: D. Schlossberg), W. B.
Saunders, Philadelpha, 1999, p. 3.
[2] C. Dye, J. Am. Med. Assoc. 1999, 282, 677–686.
[3] M. W. Borgdorff, Bull. World Health Organia. 2002, 80, 501–
502.
[4] D. E. J. Snider, M. Raviglione, A. Kochi in Tuberculosis: Patho-
genesis Protection and Control (Ed.: B. R. Bloom), American
Society of Microbiology, Washington, DC, 1994, p. 2.
5.0
3.12
0.31
0.2
[5] A. M. Rouhi, Chem. Eng. News 1999, 77, 52–69.
[6] C. Dye, 4th World Congress on TB, Washington DC, 2002, p.
Isoniazid
Rifampicin
1.0
3.
[7] D. Maher, K. Floyd, M. Ravglione, World Health Organiza-
a)
Minimal inhibitory concentration (MIC) is expressed in lg/
mL.
tion, Geneva, Switzerland, 2002, p. 1.
[8] D. E. C. Weil in Tuberculosis: Back to the Future, (Eds.: J. D. H.
Porter, K. P. W. J. McAdam), Wiley and Sons Ltd., London,
1994, p. 123–143.
tral, and elemental analysis data of the synthesized compounds
are depicted in Tables 1 and 2, respectively.
[9] J. B. Bass, L. S. Farer, P. C. Hopewell, R. O'Brien, et al., Am. J.
Respir. Crit. Care Med. 1994, 149, 1359–1374.
[10] A. Rattan, A. Kalia, N. Ahmad, Emerg. Infect. Dis. 1998, 4,
General procedure for N-(3-chloro-2-oxo-4-
195–209.
(substituted)aryl/heteroarylazetidin-1-yl) isonicotinamide
3a–g
[11] C. E. Barry, R. A. Slayden, A. E. Sampson, R. E. Lee, Biochem.
Pharmacol. 2000, 59, 221–231.
To a constantly stirred solution of the particular N9-(substituted)
arylidene/heteroarylidene isonicotinylhydrazide (1a–g, 0.01
mol) and triethylamine (0.01 mol) in dry dioxan (40 mL), chloro-
acetyl chloride (0.015 mol) was added dropwise at 0-58C. The
reaction mixture was stirred for 15–20 h and the excess of sol-
vent was distilled off under reduced pressure. The resulting
residual mass was cooled, poured into ice water, filtered, washed
with water, dried. Recrystallization from the proper solvents
yielded the title compounds 3a–g. The physicochemical, spec-
tral, and elemental analysis data of the synthesized compounds
are depicted in Tables 3 and 4, respectively.
[12] M. C. da Silva Lourenꢀo, M. de Lima Ferreira, M. V. Nora de
Souza, M. A. Peralta, et al., Eur. J. Med. Chem. 2008, 43,
1344–1347.
[13] Y. L. Janin, Bioorg. Med. Chem. 2007, 15, 2479–2513.
[14] M. G. Mamolo, D. Zampieri, V. Falagiani, L. Vio, et al., Far-
maco 2001, 56, 593–599.
[15] L. M. Fu, T. M. Shinnick, Tuberculosis 2007, 87, 63–70.
[16] H. Marrakchi, G. Laneelle, A. Quemard, Microbiology 2000,
146, 289–296.
[17] C. G. Bonde, N. J. Gaikwad, Bioorg. Med. Chem. 2004, 12,
2151–2161.
Antimycobacterial activity
[18] N. Karali, E. Ilhan, A. Gꢁrsoy, M. Kiraz, II Farmaco 1998, 53,
The antimycobacterial activity of the newly synthesized com-
pounds was assessed against M. tuberculosis ATTC 27294 using
the micro-plate Alamar Blue assay (MABA) [35]. Succinctly,
200 mL of sterile de-ionized water was added to all outer-perime-
ter wells of sterile 96-well plates (falcon 3072: Becton Dickinson,
Lincoln Park, NJ, USA) to minimize evaporation of the medium
in the test wells during incubation. The 96-well plates received
100 mL of the Middlebrook 7H9 broth (Difco laboratories,
Detroit, MI, USA) and a serial dilution of the compounds 2a–g
and 3a–g was made directly on the plate. The final drug concen-
trations tested were 0.01–20.0 lg/mL. Plates were covered and
sealed with parafilm and incubated at 378C for five days. After
this time, 25 lL of a freshly prepared 1 : 1 mixture of Alamar
Blue reagent (Accumed International, Westlake, OH, USA) and
10% tween 80 was added to the plate and incubated for 24 h. A
blue color in the well was interpreted as no bacterial growth,
and a pink color was scored as growth. The MIC was defined as
346–349.
[19] M. L. Barreca, A. Chimirri, L. D. Luca, A. M. Monforte, et al.,
Bioorg. Med. Chem. Lett. 2001, 11, 1793–1796.
[20] N. Ulusoy, Arzneimittelforschung 2002, 52, 565–571.
[21] C. J. Andres, J. J. Bronson, S. V. D'Andrea, M. S. Deshpande,
et al., Bioorg. Med. Chem. Lett. 2000, 10, 715–717.
[22] N. M. Shirode, K. C. Kulkarni, V. K. Gumatse, A. R. A. S.
Deshmukh, ARKIVOC 2005, I, 53–64.
[23] G. S. Singh, Mini-Rev. Med. Chem. 2004, 4, 69–92.
[24] A. R. A. S. Deshmukh, B. M. Bhawal, D. Krishnaswami, V. V.
Govande, et al., Curr. Med. Chem. 2004, 11, 1889–1920.
[25] V. S. Maddi, R. S. Kallur, M. N. A. Rao, J. Pharm. Sci. 1992, 81,
964–966.
[26] G. Bolakatti, V. Maddi, S. N. Mamledesai, P. M. Ronad, et
al., Arzneimittelforschung 2008, 58, 515–520.
i 2009 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim